Screener
Rigel Pharmaceuticals RIGL Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Rigel Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
FAQ
- What is Rigel Pharmaceuticals's return on equity?
- Rigel Pharmaceuticals (RIGL) reported return on equity of 174.1% in Q1 2026.
- What is the long-term trend for Rigel Pharmaceuticals's return on equity?
- Over 2 years (2020 to 2025), Rigel Pharmaceuticals's return on equity has grown at a 65.7% compound annual growth rate (CAGR), from -67.7% to 185.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Rigel Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude